GOALS OF WORK: We evaluated piperacillin-tazobactam in association with netilmicin (TN) in the early empirical treatment of neutropenic children, as data are limited in number. PATIENTS AND METHOD: In 1996, an observational study was initiated to assess the efficacy and safety of this association, with a glycopeptide (TNG) if needed. The impact on the bacterial ecology of our unit was also observed. Children were treated for hematological malignancy or solid tumor between September 1996 and December 1998 and presented a febrile neutropenia. RESULTS: There were 148 evaluable febrile neutropenic episodes in 104 patients. Median age was 7 years, 55% of the episodes were fever of unknown origin, 22% were clinically documented and 23% microbiologically documented (27 bacteriemia). A glycopeptide was added in 67 episodes. The initial unmodified treatment was successful in 114 episodes (77%): 75/81 episodes in the TN group and 39/67 in the TNG group. For successful episodes, median treatment duration was 6 days. There were 22 febrile recurrences. These patients, as well as initial failures, always responded to a second-line treatment. One child was considered a failure because he developed a skin rash probably due to piperacillin-tazobactam and required another beta-lactamase. CONCLUSION: This study suggests that piperacillin-tazobactam in association with netilmicin presents a satisfactory efficacy and a good tolerance as empirical therapy for febrile neutropenic children. It allowed us to maintain the bacterial ecology of our unit.
GOALS OF WORK: We evaluated piperacillin-tazobactam in association with netilmicin (TN) in the early empirical treatment of neutropenicchildren, as data are limited in number. PATIENTS AND METHOD: In 1996, an observational study was initiated to assess the efficacy and safety of this association, with a glycopeptide (TNG) if needed. The impact on the bacterial ecology of our unit was also observed. Children were treated for hematological malignancy or solid tumor between September 1996 and December 1998 and presented a febrile neutropenia. RESULTS: There were 148 evaluable febrile neutropenic episodes in 104 patients. Median age was 7 years, 55% of the episodes were fever of unknown origin, 22% were clinically documented and 23% microbiologically documented (27 bacteriemia). A glycopeptide was added in 67 episodes. The initial unmodified treatment was successful in 114 episodes (77%): 75/81 episodes in the TN group and 39/67 in the TNG group. For successful episodes, median treatment duration was 6 days. There were 22 febrile recurrences. These patients, as well as initial failures, always responded to a second-line treatment. One child was considered a failure because he developed a skin rash probably due to piperacillin-tazobactam and required another beta-lactamase. CONCLUSION: This study suggests that piperacillin-tazobactam in association with netilmicin presents a satisfactory efficacy and a good tolerance as empirical therapy for febrile neutropenicchildren. It allowed us to maintain the bacterial ecology of our unit.
Authors: J Feliu; A Artal; M González Barón; A Berrocal; I Chacón; M L García de Paredes; E Espinosa; A Ordóñez; P Zamora; J M Montero Journal: Antimicrob Agents Chemother Date: 1992-12 Impact factor: 5.191
Authors: W T Hughes; D Armstrong; G P Bodey; A E Brown; J E Edwards; R Feld; P Pizzo; K V Rolston; J L Shenep; L S Young Journal: Clin Infect Dis Date: 1997-09 Impact factor: 9.079
Authors: I I Raad; E E Whimbey; K V Rolston; D Abi-Said; R Y Hachem; R G Pandya; H M Ghaddar; C L Karl; G P Bodey Journal: Cancer Date: 1996-04-01 Impact factor: 6.860
Authors: A Simon; T Lehrnbecher; U Bode; A H Groll; L Tramsen; R Wieland; E Molitor; G Fleischhack; H J Laws Journal: Eur J Clin Microbiol Infect Dis Date: 2007-11 Impact factor: 5.103